Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kasra Amirdelfan

Pain Medicine Walnut Creek, CA Medical Doctor

NPI 1033113642 CMS profile 319261

450 N Wiget Ln, Walnut Creek, CA 94598

Open in the dashboard

General payments

$783,277

814 records reported · program years 2019–2025

Research payments

$5,016

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$959,175 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kasra Amirdelfan of Walnut Creek, CA is reported in the CMS Open Payments database as having received $783,277 across 814 general payments and $5,016 in research payments paid to them. Separately, studies naming them as principal investigator received $959,175 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,554 24
2024 General $19,247 50
2023 General $59,628 53
2022 General $111,348 135
2021 General $158,752 169
2021 Research $16 1
2020 General $158,313 141
2020 Research $5,000 4
2019 General $262,435 242

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kasra Amirdelfan
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kasra Amirdelfan were reported at $13,554. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Kasra Amirdelfan Pain Medicine median Middle half National median
2019 $262,435 $506 $144–$1,566 $163
2020 $158,313 $315 $96–$934 $114
2021 $158,752 $452 $134–$1,237 $132
2022 $111,348 $475 $124–$1,407 $149
2023 $59,628 $480 $136–$1,384 $160
2024 $19,247 $521 $164–$1,511 $164
2025 $13,554 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $526,279 492 payments
  2. Biotronik Inc. $114,354 38 payments
  3. Painteq LLC $30,537 88 payments
  4. Medtronic, Inc. $27,469 28 payments
  5. BIOTRONIK NRO, Inc. $25,167 37 payments
  6. Medtronic USA, Inc. $22,470 31 payments
  7. Nalu Medical, Inc. $15,013 10 payments
  8. Saluda Medical Americas, Inc. $11,231 22 payments
  9. Boston Scientific Corporation $4,417 11 payments
  10. Globus Medical, Inc. $4,285 4 payments
  11. Other $2,056 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $380,821 243 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $146,300 32 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $81,700 40 payments
  4. Travel and Lodging $69,642 121 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,500 26 payments
  6. Food and Beverage $26,243 347 payments
  7. Current or prospective ownership or investment interest $12,554 4 payments
  8. Acquisitions $10,518 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $318,380 272 payments
  2. Omnia $184,541 186 payments
  3. PAINTEQ $30,537 88 payments
  4. Senza $21,394 14 payments
  5. Nalu Neurostimulation System $15,013 10 payments
  6. INTELLIS $11,680 19 payments
  7. Prospera Not Applicable $11,453 7 payments
  8. Prospera Not Applicable $7,709 15 payments
  9. Evoke SCS $6,383 13 payments
  10. BIOTRONIK $6,349 3 payments
  11. Other $32,251 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $5,016 5 payments

Records

819 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record